Vaccine Innovations Zambia (VIZ)
Investment Prospectus · 2025–2030

Vaccine Innovations
Zambia (VIZ)

Establishing a locally manufactured vaccine industry in Zambia — reducing import dependence, protecting food security, and positioning Zambia as the biosecurity hub of Southern Africa.

US$12–13M
Annual vaccine imports · Zambia
US$1–2M
Feasibility funding sought
SADC
Regional export target
01
Food Security
Protection at scale
02
Economic Growth
Import substitution
03
Pandemic Prevention
One Health approach
04
Regional Leadership
SADC vaccine hub
Background & Rationale

A critical gap in Southern Africa's animal health system

Zambia's animal production sector — spanning smallholder and commercial poultry and livestock — is a critical engine of food security, rural income, and national economic growth. Yet recurrent disease outbreaks continue to erode productivity and sustain deep dependence on imported veterinary vaccines.

Imported vaccines are frequently ill-matched to locally circulating strains and are constrained by fragile cold-chain infrastructure, severely limiting their effectiveness in rural and pastoral settings where disease pressure is highest.

This initiative proposes an animal vaccine R&D and manufacturing facility in Zambia — structured through a public-private partnership model under a hybrid university-based incubation and joint-venture governance framework, with the Industrial Development Corporation (IDC) of Zambia as primary institutional anchor.

Livestock in Zambia
Zambian livestock farming · December 2025
Strategic Objectives

What this initiative will achieve

01
Establish Vaccine Manufacturing in Zambia
Build a GMP-compliant, pilot-to-commercial scale manufacturing facility for NDV and FMD vaccines — eliminating cold-chain dependence and enabling year-round rural deployment.
02
Secure Feasibility Funding (US$1–2M)
Engage USTDA, USAID, DFC, Afreximbank, and the Gates Foundation with tailored value propositions to secure 2+ funding agreements covering the comprehensive feasibility phase.
03
Formalize the IDC Joint Venture & SPV Structure
Establish a public-private co-owned operating entity under IDC Zambia with clear equity, IP ownership, governance rights, and dividend policy frameworks.
04
Reduce Zambia's US$12–13M Annual Import Bill
Replace imported, strain-mismatched vaccines with locally produced alternatives — retaining economic value domestically and improving vaccine efficacy under Zambian field conditions.
05
Develop Technology Transfer Partnerships
Identify and secure agreements with 2–3 biotech companies holding validated NDV and FMD technology, including IP protection frameworks and cGMP manufacturing standards.
06
Position Zambia as a SADC Regional Vaccine Hub
Develop a regional export strategy targeting the SADC market — leveraging Zambia's location, regulatory environment, and manufacturing capacity to supply neighboring countries.
Priority 1
Target Species: Poultry (Chickens)

Newcastle Disease Vaccine

Newcastle Disease is among the most economically devastating poultry diseases in Zambia, with recurring outbreaks during rainy seasons that devastate both smallholder livelihoods and commercial operations. Cold-chain failures and strain mismatch have severely undermined existing imported vaccine effectiveness.

Priority 2
Target Species: Livestock (Cattle, Pigs)

Foot & Mouth Disease Vaccine

Foot and Mouth Disease is a highly contagious transboundary disease that devastates cattle and pig populations, restricts trade, and poses ongoing regional spillover risks across Southern Africa. Reliance on imported FMD vaccines without genotype matching leaves herds critically vulnerable.

Implementation Roadmap

Four phases to commercial launch

A structured, milestone-driven pathway from feasibility through to full commercial production and SADC regional export — anchored by world-class scientific leadership and institutional governance.

Phase 1
Months 1–6
Foundation Setting
  • Convene inaugural Steering Committee; ratify Terms of Reference
  • Prioritize donors: USTDA, USAID/DFC, Afreximbank, BMGF
  • Engage IDC Zambia leadership; align on joint venture structure
  • Formalize Letter of Intent between BIOVAC Nepal and IDC Zambia
Phase 2
Months 4–12
Resource Mobilization
  • Prepare and submit comprehensive feasibility proposals
  • Develop detailed US$1–2M feasibility budget
  • Register co-owned operating company in Zambia
  • Recruit Zambia-based core scientific team
✦ Milestone: Feasibility funding secured — US$1–2M
Phase 3
Year 1–2
Feasibility Assessment
  • Commission comprehensive NDV burden assessment
  • Assess FMD serotype prevalence in Zambian populations
  • Evaluate modular facility designs from pilot to commercial scale
  • Secure MoUs with 2–3 technology partners
✦ Milestone: Business plan & investment case validated
Phase 4
Year 2–5
Pilot Build & Commercialization
  • Construct GMP-aligned modular pilot facility
  • Initiate pilot-scale production of NDV vaccine
  • Deploy cold-chain-free NDV field trials across 2–3 provinces
  • Initiate SADC regional export strategy
✦ Milestone: Commercial launch · SADC export initiated
Zambian wildlife — wildebeest and zebra
"Vaccinating Africa from within — reducing import dependence, improving efficacy, and creating a sustainable domestic industry."
Vaccine Innovations Zambia · One Health Initiative
Steering Committee

World-class leadership across every discipline

Prof. Kaampwe Muzandu
Prof. Kaampwe Muzandu
Strategic Scientific & Regulatory Lead
Acting Dean, SVM · University of Zambia
Zambian veterinarian and associate professor recognized for leadership in One Health across veterinary pharmacology, toxicology, food safety, and epidemiology. Chairs ZAMRA's Technical Committee on Clinical Trials and Pharmacovigilance.
Michelo Simuyandi
Michelo Simuyandi, MSc
Translational Research Lead
Technical Lead, ZVMI · CIDRZ
Molecular and Cell Biologist with expertise spanning translational research, clinical development, and vaccine manufacturing strategy. Works at the interface of science, policy, and industrial development to advance vaccine R&D in Africa.
Dr. Fred Cassels
Dr. Fred Cassels, PhD
Vaccine R&D Science
Senior Program Director · Human Immunome Project
Biochemist, microbiologist, and immunologist with a long history in vaccine development including adjuvant and delivery system studies, and preclinical and Phase I–IV clinical trials for global public health. Formerly WRAIR and NIAID.
Dr. William Kilembe
Dr. William Kilembe, MBChB
Clinical Research Leader
Senior Leadership · IAVI / CFHRZ, Zambia
Physician-scientist and clinical research leader with extensive experience in Phase I–III clinical trials in Zambia. Has helped establish Zambia as a key site for high-quality biomedical research in sub-Saharan Africa.
Dr. Musaku Mwenechanya
Dr. Musaku Mwenechanya
Immunization Policy
Senior Pediatrician, UTH · Chair, ZITAG
National leader in immunization policy and child health. Chair of ZITAG, providing independent evidence-based guidance to the Ministry of Health on vaccine policy, introduction decisions, safety monitoring, and program optimization.
Dr. Dibesh Karmacharya
Dr. Dibesh Karmacharya, PhD
Manufacturing & Technology
BIOVAC Nepal · University of Queensland
Biotechnology scientist and entrepreneur advancing locally manufactured vaccines for LMICs. Leads BIOVAC Nepal across poultry and human vaccines, integrating R&D, GMP manufacturing, and regulatory pathways from lab to market.
Dr. David Bunn
Dr. David Bunn, PhD
One Health Specialist
Independent Consultant · Formerly University of California Davis
Leading One Health specialist focused on the wildlife–livestock–human interface, zoonotic spillover risk, and community-based disease prevention. With extensive experience across Africa, Asia, and the United States, he advises governments and global partners on risk-based vaccination approaches and locally suitable vaccine delivery models in pastoral and rural communities.
Partner With Us

Vaccinate Africa from within

We are seeking feasibility-phase funding and strategic partners to unlock this transformational initiative. Your investment will directly reduce disease burden, protect food security, and build lasting scientific capacity in Zambia and across Southern Africa.

US$1–2M
Feasibility Phase — Funding Target
Scope Disease burden assessment, facility design
Technology demonstration NDV & FMD platform validation
Regulatory mapping ZAMRA pathways & GMP standards
Governance structure IDC Zambia JV · SPV · University of Zambia
Target partners USTDA, USAID/DFC, Afreximbank, BMGF
Version Prospectus v2.0 · March 2026